[en] SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman's r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the "Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit" and the "Genscript cPass, kit" revealed an overall good correlation ranging from 0.8673 to -0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (n = 100) and an Omicron-breakthrough infection cohort (n = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs.
Disciplines :
Microbiology
Author, co-author :
Santos da Silva, Eveline ; Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
Servais, Jean-Yves; Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
Kohnen, Michel; National Service of Infectious Diseases, Centre Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, Luxembourg
Arendt, Vic; National Service of Infectious Diseases, Centre Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, Luxembourg
Staub, Therese; National Service of Infectious Diseases, Centre Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, Luxembourg
The Con-Vince Consortium
The CoVaLux Consortium
Krüger, Rejko ; Transversal Translational Medicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg, 4 rue Ernest Barblé, L-1210 Luxembourg, Luxembourg ; Translational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 6 avenue du Swing, L-4367 Belvaux, Luxembourg
FAGHERAZZI, Guy ; University of Luxembourg ; Department of Precision Health, Luxembourg Institute of Health, 1AB Rue Thomas Edison, L-1445 Strassen, Luxembourg
WILMES, Paul ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Systems Ecology ; Systems Ecology Group, Luxembourg Centre for Systems Biomedicine, 7 Avenue des Hauts Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
Hübschen, Judith M ; Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
OLLERT, Markus ; University of Luxembourg ; Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
Perez-Bercoff, Danielle ; Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
Seguin-Devaux, Carole ; Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
H2020 - 101016167 - ORCHESTRA - Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic: ORCHESTRA
FnR Project :
FNR14718697 - A Novel High Throughput Assay To Measure Plasma Neutralizing Activity Against Sars-cov-2 Against Sars-cov-2, 2020 (01/06/2020-30/11/2020) - Danielle Perez Bercoff FNR14716281 - 2020 (01/04/2020-30/09/2022) - Rejko Krueger FNR14716273 - 2020 (01/04/2020-30/06/2022) - Guy Fagherazzi
Funders :
Luxembourg National Research Fund Rotary Club Luxembourg EATRIS TRANSVAC-2 Ministère de l’Education et de la Recherche du Luxembourg Fonds National de la Recherche André Losch Foundation European Union’s Horizon 2020 research and innovation programme Luxembourg National Research Fund the André Losch Foundation European Regional Development Fund Luxembourg Government Union Européenne
Funding text :
The authors are thankful to all the participants. Some of the data used in the preparation of this manuscript were obtained from the CON-VINCE and the Predi-COVID studies. We acknowledge the involvement of the interdisciplinary and inter-institutional study teams of research Luxembourg that contributed to CON-VINCE and Predi-COVID studies. The full list of the Predi-COVID team can be found here: https://sites.lih.lu/the-predi-COVID-study/about-us/project-team/ (accessed on 21 May 2023). We acknowledge the joint effort of the CoVaLux Consortium members from the partner institutions contributing to the translational research CoVaLux programme. The work was further supported by the Luxembourg Government through the CoVaLux programme. We thank the Research Luxembourg COVID-19 Task Force, the Ministry of Health of Luxembourg and the Directorate of Health of Luxembourg for their support to the CON-VINCE and Predi-COVID studies. We are grateful to Philippe Lamesch for successful fundraising for research on COVID-19 in Luxembourg. We are thankful to the communication teams involved in the CON-VINCE study: Sabine Schmitz, Arnaud D’Agostini, Didier Gossens, Hélène Jacuszin. We thank the Convince cortium and the CoVaLux consortium () as well as the Robert Koch Institute, Germany, for providing Vero-E6 cells when none had any.This research was funded by the Luxembourg National Research Fund (FNR) (NEUTRACOV, grant number 14718697), the Rotary Club Luxembourg, EATRIS TRANSVAC-2, and the Ministère de l’Education et de la Recherche du Luxembourg. The CON-VINCE study was supported by the Fonds National de la Recherche (FNR: 14716281/CON-VINCE/Kruger), and the André Losch Foundation (Luxembourg). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016167. The Predi-COVID study was supported by the Luxembourg National Research Fund (FNR) (Predi-COVID, grant number 14716273), the André Losch Foundation, and the European Regional Development Fund (FEDER, convention 2018-04-026-21). The work was further supported by the Luxembourg Government through the CoVaLux programme. The funders had no role in the design and conduct of the study, nor in the decision to prepare and submit the manuscript for publication.
Murray C.J.L. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through 14 November 2021: A statistical analysis Lancet 2022 399 2351 2380
Tao K. Tzou P.L. Nouhin J. Gupta R.K. de Oliveira T. Kosakovsky Pond S.L. Fera D. Shafer R.W. The biological and clinical significance of emerging SARS-CoV-2 variants Nat. Rev. Genet. 2021 22 757 773 10.1038/s41576-021-00408-x
Qu P. Faraone J. Evans J.P. Zou X. Zheng Y.M. Carlin C. Bednash J.S. Lozanski G. Mallampalli R.K. Saif L.J. et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants N. Engl. J. Med. 2022 386 2526 2528 10.1056/NEJMc2206725
Rossler A. Knabl L. von Laer D. Kimpel J. Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection N. Engl. J. Med. 2022 386 1764 1766 10.1056/NEJMc2201607 35320661
Goldberg Y. Mandel M. Bar-On Y.M. Bodenheimer O. Freedman L.S. Ash N. Alroy-Preis S. Huppert A. Milo R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 N. Engl. J. Med. 2022 386 2201 2212 10.1056/NEJMoa2118946 35613036
Planas D. Saunders N. Maes P. Guivel-Benhassine F. Planchais C. Buchrieser J. Bolland W.-H. Porrot F. Staropoli I. Père H. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Nature 2022 602 671 675 10.1038/s41586-021-04389-z 35016199
Carreño J.M. Alshammary H. Tcheou J. Singh G. Raskin A.J. Kawabata H. Sominsky L.A. Clark J.J. Adelsberg D.C. Bielak D.A. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron Nature 2022 602 682 688 10.1038/s41586-022-04399-5
Higdon M.M. Baidya A. Walter K.K. Patel M.K. Issa H. Espie E. Feikin D.R. Knoll M.D. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant Lancet Infect. Dis. 2022 22 1114 1116 10.1016/S1473-3099(22)00409-1
Pulliam J.R.C. Schalkwyk Cv Govender N. Gottberg Av Cohen C. Groome M.J. Dushoff J. Mlisana K. Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa Science 2022 376 eabn4947 10.1126/science.abn4947
Michlmayr D. Hansen C.H. Gubbels S.M. Valentiner-Branth P. Bager P. Obel N. Drewes B. Møller C.H. Møller F.T. Legarth R. et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data Lancet Reg. Health Eur. 2022 20 100452 10.1016/j.lanepe.2022.100452
McMahan K. Yu J. Mercado N.B. Loos C. Tostanoski L.H. Chandrashekar A. Liu J. Peter L. Atyeo C. Zhu A. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques Nature 2021 590 630 634 10.1038/s41586-020-03041-6
Deshpande K. Pt U. Kaduskar O. Vijay N. Rakhe A. Vidhate S. Khutwad K. Deshpande G.R. Tilekar B. Saka S. et al. Performance assessment of seven SARS-CoV-2 IgG enzyme-linked immunosorbent assays J. Med. Virol. 2021 93 6696 6702 10.1002/jmv.27251 34331713
Takheaw N. Liwsrisakun C. Chaiwong W. Laopajon W. Pata S. Inchai J. Duangjit P. Pothirat C. Bumroongkit C. Deesomchok A. et al. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination Diagnostics 2022 12 1315 10.3390/diagnostics12061315 35741126
Khoury D.S. Cromer D. Reynaldi A. Schlub T.E. Wheatley A.K. Juno J.A. Subbarao K. Kent S.J. Triccas J.A. Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Nat. Med. 2021 27 1205 1211 10.1038/s41591-021-01377-8 34002089
Cromer D. Steain M. Reynaldi A. Schlub T.E. Wheatley A.K. Juno J.A. Kent S.J. Triccas J.A. Khoury D.S. Davenport M.P. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis Lancet Microbe 2022 3 e52 e61 10.1016/S2666-5247(21)00267-6 34806056
Goldblatt D. Alter G. Crotty S. Plotkin S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease Immunol. Rev. 2022 310 6 26 10.1111/imr.13091 35661178
Earle K.A. Ambrosino D.M. Fiore-Gartland A. Goldblatt D. Gilbert P.B. Siber G.R. Dull P. Plotkin S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines Vaccine 2021 39 4423 4428 10.1016/j.vaccine.2021.05.063
Goldblatt D. Fiore-Gartland A. Johnson M. Hunt A. Bengt C. Zavadska D. Snipe H.D. Brown J.S. Workman L. Zar H.J. et al. Towards a population-based threshold of protection for COVID-19 vaccines Vaccine 2022 40 306 315 10.1016/j.vaccine.2021.12.006
Lustig Y. Sapir E. Regev-Yochay G. Cohen C. Fluss R. Olmer L. Indenbaum V. Mandelboim M. Doolman R. Amit S. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers Lancet Respir. Med. 2021 9 999 1009 10.1016/S2213-2600(21)00220-4
Zou J. Xie X. Liu M. Shi P.Y. Ren P. Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections mBio 2022 13 e0199622 10.1128/mbio.01996-22
Gilbert P.B. Montefiori D.C. McDermott A.B. Fong Y. Benkeser D. Deng W. Zhou H. Houchens C.R. Martins K. Jayashankar L. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Science 2022 375 43 50 10.1126/science.abm3425
Feng S. Phillips D.J. White T. Sayal H. Aley P.K. Bibi S. Dold C. Fuskova M. Gilbert S.C. Hirsch I. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Nat. Med. 2021 27 2032 2040 10.1038/s41591-021-01540-1
Regev-Yochay G. Lustig Y. Joseph G. Gilboa M. Barda N. Gens I. Indenbaum V. Halpern O. Katz-Likvornik S. Levin T. et al. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): A prospective cohort study Lancet Microbe 2023 4 e309 e318 10.1016/S2666-5247(23)00012-5 36963419
Yang Y. Du L. SARS-CoV-2 spike protein: A key target for eliciting persistent neutralizing antibodies Signal Transduct. Target. Ther. 2021 6 95 10.1038/s41392-021-00523-5 33637679
Walls A.C. Park Y.-J. Tortorici M.A. Wall A. McGuire A.T. Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cell 2020 181 281 292.e6 10.1016/j.cell.2020.02.058 32155444
Brouwer P.J.M. Caniels T.G. van der Straten K. Snitselaar J.L. Aldon Y. Bangaru S. Torres J.L. Okba N.M. Claireaux M. Kerster G. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Science 2020 369 643 650 10.1126/science.abc5902 32540902
Andreano E. Nicastri E. Paciello I. Pileri P. Manganaro N. Piccini G. Manenti A. Pantano E. Kabanova A. Troisi M. et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients Cell 2021 184 1821 1835.e16 10.1016/j.cell.2021.02.035
Amanat F. Thapa M. Lei T. Ahmed S.M.S. Adelsberg D.C. Carreño J.M. Strohmeier S. Schmitz A.J. Zafar S. Zhou J.Q. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 Cell 2021 184 3936 3948.e10 10.1016/j.cell.2021.06.005
Chi X. Yan R. Zhang J. Zhang G. Zhang Y. Hao M. Zhang Z. Fan P. Dong Y. Yang Y. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 Science 2020 369 650 655 10.1126/science.abc6952
Graninger M. Camp J.V. Aberle S.W. Traugott M.T. Hoepler W. Puchhammer-Stöckl E. Weseslindtner L. Zoufaly A. Aberle J.H. Stiasny K. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination Front. Immunol. 2022 13 888794 10.3389/fimmu.2022.888794
Greaney A.J. Loes A.N. Gentles L.E. Crawford K.H.D. Starr T.N. Malone K.D. Chu H.Y. Bloom J.D. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection Sci. Transl. Med. 2021 13 eabi9915 10.1126/scitranslmed.abi9915 34103407
Voss W.N. Hou Y.J. Johnson N.V. Delidakis G. Kim J.E. Javanmardi K. Horton A.P. Bartzoka F. Paresi C.J. Tanno Y. et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes Science 2021 372 1108 1112 10.1126/science.abg5268 33947773
Lippi G. Adeli K. Plebani M. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: Urgent call for validation against new and highly mutated variants Clin. Chem. Lab. Med. 2021 60 338 342 10.1515/cclm-2021-1287
Sholukh A.M. Fiore-Gartland A. Ford E.S. Miner M.D. Hou Y.J. Tse L.V. Kaiser H. Zhu H. Lu J. Madarampalli B. et al. Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays J. Clin. Microbiol. 2021 59 e0052721 10.1128/JCM.00527-21 34288726
Hofmann N. Grossegesse M. Neumann M. Schaade L. Nitsche A. Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2 Sci. Rep. 2022 12 3549 10.1038/s41598-022-07597-3
Meyer B. Reimerink J. Torriani G. Brouwer F. Godeke G.J. Yerly S. Hoogerwerf M. Vuilleumier N. Kaiser L. Eckerle I. et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT) Emerg. Microbes Infect. 2020 9 2394 2403 10.1080/22221751.2020.1835448 33043818
Mouna L. Razazian M. Duquesne S. Roque-Afonso A.M. Vauloup-Fellous C. Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers Viruses 2023 15 426 10.3390/v15020426
Merluza J. Ung J. Makowski K. Robinson A. Manguiat K. Mueller N. Audet J. Chen J.C.Y. Strong J.E. Wood H. et al. Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test Microbiol. Spectr. 2023 11 e0378922 10.1128/spectrum.03789-22
Dejnirattisai W. Huo J. Zhou D. Zahradník J. Supasa P. Liu C. Duyvesteyn H.M. Ginn H.M. Mentzer A.J. Tuekprakhon A. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Cell 2022 185 467 484.e15 10.1016/j.cell.2021.12.046
Springer D.N. Perkmann T. Jani C.M. Mucher P. Pruger K. Marculescu R. Reuberger E. Camp J.V. Graninger M. Borsodi C. et al. Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant Microbiol. Spectr. 2022 10 e0212922 10.1128/spectrum.02129-22
Saker K. Pozzetto B. Escuret V. Pitiot V. Massardier-Pilonchery A. Mokdad B. Langlois-Jacques C. Rabilloud M. Alfaiate D. Guibert N. et al. Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects J. Clin. Virol. 2022 152 105169 10.1016/j.jcv.2022.105169
Suntronwong N. Assawakosri S. Kanokudom S. Yorsaeng R. Auphimai C. Thongmee T. Vichaiwattana P. Duangchinda T. Chantima W. Pakchotanon P. et al. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination Diagnostics 2022 12 1781 10.3390/diagnostics12081781
Kanokudom S. Assawakosri S. Suntronwong N. Auphimai C. Nilyanimit P. Vichaiwattana P. Thongmee T. Yorsaeng R. Srimuan D. Thatsanatorn T. et al. Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine Vaccines 2022 10 86 10.3390/vaccines10010086
Da Silva E.S. Kohnen M. Gilson G. Staub T. Arendt V. Hilger C. Servais J.Y. Charpentier E. Domingues O. Snoeck C.J. et al. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone Int. J. Mol. Sci. 2022 23 7675 10.3390/ijms23147675 35887023
Embregts C.W.E. Verstrepen B. Langermans J.A.M. Boszormenyi K.P. Sikkema R.S. de Vries R.D. Hoffmann D. Wernike K. Smit L.A. Zhao S. et al. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test One Health 2021 13 100313 10.1016/j.onehlt.2021.100313 34458548
Taylor S.C. Hurst B. Charlton C.L. Bailey A. Kanji J.N. McCarthy M.K. Morrison T.E. Huey L. Annen K. DomBourian M.G. et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection J. Clin. Microbiol. 2021 59 10 1128 10.1128/JCM.02438-20 33500361
Da Silva E.S. Servais J.-Y. Kohnen M. Arendt V. Gilson G. Staub T. Seguin-Devaux C. Perez-Bercoff D. Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone Curr. Issues Mol. Biol. 2023 45 1741 1761 10.3390/cimb45020112 36826057
Rössler A. Netzl A. Knabl L. Schäfer H. Wilks S.H. Bante D. Falkensammer B. Borena W. von Laer D. Smith D.J. et al. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants Nat. Commun. 2022 13 7701 10.1038/s41467-022-35312-3 36513653
Iketani S. Liu L. Guo Y. Liu L. Chan J.F. Huang Y. Antibody evasion properties of SARS-CoV-2 Omicron sublineages Nature 2022 604 553 556 10.1038/s41586-022-04594-4
Levin E.G. Lustig Y. Cohen C. Fluss R. Indenbaum V. Amit S. Doolman R. Asraf K. Mendelson E. Ziv A. et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months N. Engl. J. Med. 2021 385 e84 10.1056/NEJMoa2114583
Garcia-Beltran W.F. Denis K.S. Hoelzemer A. Lam E.C. Nitido A.D. Sheehan M.L. Berrios C. Ofoman O. Chang C.C. Hauser B.M. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant Cell 2022 185 457 466.e4 10.1016/j.cell.2021.12.033
Graninger M. Jani C.M. Reuberger E. Pruger K. Gaspar P. Springer D.N. Borsodi C. Weidner L. Rabady S. Puchhammer-Stöckl E. et al. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference Microbiol. Spectr. 2023 11 e0231422 10.1128/spectrum.02314-22 36622205
Andrews N. Stowe J. Kirsebom F. Toffa S. Sachdeva R. Gower C. Ramsay M. Bernal J.L. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England Nat. Med. 2022 28 831 837 10.1038/s41591-022-01699-1 35045566
Hvidt A.K. Baerends E.A.M. Søgaard O.S. Stærke N.B. Raben D. Reekie J. Nielsen H. Johansen I.S. Wiese L. Benfield T.L. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines Front. Med. 2022 9 994160 10.3389/fmed.2022.994160 36262278
Adams O. Andree M. Hermsen D. Lubke N. Timm J. Schaal H. Müller L. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts J. Virol. Methods 2022 307 114569 10.1016/j.jviromet.2022.114569 35724697
Naaber P. Tserel L. Kangro K. Sepp E. Jürjenson V. Adamson A. Haljasmägi L. Rumm A.P. Maruste R. Kärner J. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study Lancet Reg. Health-Eur. 2021 10 100208 10.1016/j.lanepe.2021.100208 34514454
Muller K. Girl P. von Buttlar H. Dobler G. Wolfel R. Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2 J. Virol. Methods 2021 292 114122 10.1016/j.jviromet.2021.114122
Papenburg J. Cheng M.P. Corsini R. Caya C. Mendoza E. Manguiat K. Lindsay L.R. Wood H.A. Drebot M. Dibernardo A. et al. Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay Open Forum Infect. Dis. 2021 8 ofab220 10.1093/ofid/ofab220
Mahmoud S.A. Ganesan S. Naik S. Bissar S. Zamel I.A. Warren K.N. Zaher W.A. Khan G. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response Microbiol. Spectr. 2021 9 e0073321 10.1128/Spectrum.00733-21
Kruttgen A. Lauen M. Klingel H. Imohl M. Kleines M. Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273 J. Virol. Methods 2022 299 114297 10.1016/j.jviromet.2021.114297
Malato J. Ribeiro R.M. Leite P.P. Casaca P. Fernandes E. Antunes C. Fonseca V.R. Gomes M.C. Graca L. Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants N. Engl. J. Med. 2022 387 953 954 10.1056/NEJMc2209479 36044619
